133510-16-4

Basic information

• Product Name: 5-Chlorocarbonyl-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester
• Synonyms: 5-Chlorocarbonyl-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester
• CAS NO: 133510-16-4
• Molecular Weight: 374.651
• Mol File: 133510-16-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-Chlorocarbonyl-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chlorocarbonyl-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester(133510-16-4)
• EPA Substance Registry System: 5-Chlorocarbonyl-4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3-carboxylic acid methyl ester(133510-16-4)

Safety Data

• Hazardous Substances Data: 133510-16-4(Hazardous Substances Data)

Upstream product

• 123853-39-4 (+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-5-methoxycarbonyl-3-pyridinecarboxylic acid 

Relevant articles and documents

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.